ATOS earnings analysis
What we found in ATOS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Atossa Therapeutics, Inc. reported significant operating losses in Q1 2026 with an EPS of -0.03, falling short of consensus expectations. Revenue remains non-existent, reflecting ongoing challenges in monetizing their product development despite promising research efforts. Management expressed continued uncertainties about future capital and operational viability, indicating reliance on further funding to sustain activities going forward.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Beat Expectations
- Reported EPS was -0.03, exceeding estimates of -1.11 by 0.973.
- No Revenue Generated
- Total revenue for Q1 2026 stood at $0, consistent with the previous quarters.
- Increased Operating Expenses
- Operating expenses rose to $9.9 million in Q1 2026, up from $7.4 million in Q1 2025.
- Cash Position Decline
- Cash and cash equivalents decreased to $31.7 million as of March 31, 2026.
- R&D Expense Increase
- R&D expenses rose 15%, from $4.15 million in Q1 2025 to $4.78 million in Q1 2026.
- Management Signals Ongoing Losses
- Management warns about future capital needs and expresses doubt about the ability to continue operations without additional funding.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant Operating Losses
- Net loss for Q1 2026 was $9.6 million, highlighting ongoing financial challenges.
- Lack of Revenue Sources
- The company has not established a source of revenue, raising liquidity concerns.
- Capital Raising Risks
- Management indicates the need for substantial capital to sustain operations without assurance of successful fundraising.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.03
What they said about what is next.
Management did not provide specific numeric guidance in the filing.
The filing reads worse than the one before it.
What came before.
- 10-K · March 25, 2026
- Atossa is a clinical-stage biopharmaceutical company focused on developing oral (Z)-endoxifen across multiple Phase 2 programs in ER+ breast cancer and exploring rare disease indications (e.g., DMD, MAS). The company…
- 10-K · March 25, 2025
- Atossa is a clinical-stage biopharmaceutical company focused on developing oral (Z)-endoxifen for breast cancer prevention and treatment. The 10-K highlights multiple Phase 2 data readouts showing biomarker and imaging…
- 10-Q · November 13, 2023
- Atossa reported a Q3 2023 net loss of $6,229 (loss per share $(0.05)), an improvement from Q3 2022 net loss of $8,011 (loss per share $(0.06)). Cash declined to $94,031 (from $110,890 at Dec 31, 2022) but management…
- 10-Q · August 14, 2023
- Atossa reported a Q2 net loss of $9,830,000 (loss per share $0.08) versus a prior-year Q2 net loss of $6,672,000 (loss per share $0.05), driven by higher operating expenses and a $2,990,000 impairment on an equity…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ATOS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever